<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0004349'>Reduced bone mineral density</z:hpo> (<z:hpo ids='HP_0000938'>osteopenia</z:hpo>) is a poorly characterized manifestation of pediatric and adult patients afflicted with <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>), a <z:e sem="disease" ids="C0559758" disease_type="Disease or Syndrome" abbrv="">multisystem disorder</z:e> caused by structural or quantitative defects in fibrillin-1 that perturb tissue integrity and TGFβ bioavailability </plain></SENT>
<SENT sid="1" pm="."><plain>Here we report that mice with progressively severe <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> (Fbn1(mgR/mgR) mice) develop <z:hpo ids='HP_0000938'>osteopenia</z:hpo> associated with <z:mpath ids='MPATH_458'>normal</z:mpath> osteoblast differentiation and bone formation </plain></SENT>
<SENT sid="2" pm="."><plain>In vivo and ex vivo experiments, respectively, revealed that adult Fbn1(mgR/mgR) mice respond more strongly to locally induced <z:hpo ids='HP_0002797'>osteolysis</z:hpo> and that Fbn1(mgR/mgR) osteoblasts stimulate pre-osteoclast differentiation more than <z:mp ids='MP_0002169'>wild-type</z:mp> cells </plain></SENT>
<SENT sid="3" pm="."><plain>Greater osteoclastogenic potential of mutant osteoblasts was largely attributed to Rankl up-regulation secondary to improper TGFβ activation and signaling </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="6541">Losartan</z:chebi> treatment, which lowers TGFβ signaling and restores aortic wall integrity in mice with mild <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>, did not mitigate bone loss in Fbn1(mgR/mgR) mice even though it ameliorated <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Conversely, <z:chebi fb="0" ids="2567">alendronate</z:chebi> treatment, which restricts osteoclast activity, improved bone quality but not <z:hpo ids='HP_0002617'>aneurysm</z:hpo> progression in Fbn1(mgR/mgR) mice </plain></SENT>
<SENT sid="6" pm="."><plain>Taken together, our findings shed new light on the pathogenesis of <z:hpo ids='HP_0000938'>osteopenia</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>, in addition to arguing for a multifaceted treatment strategy in this <z:e sem="disease" ids="C0242354" disease_type="Disease or Syndrome" abbrv="">congenital disorder</z:e> of the connective tissue </plain></SENT>
</text></document>